Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor
Connull Leslie, Samantha Bowyer, Alison White, et al.
Pathology (2015) Vol. 47, Iss. 6, pp. 557-563
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Overcoming Immune Evasion in Melanoma
Kevinn Eddy, Suzie Chen
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 8984-8984
Open Access | Times Cited: 161
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Italia Falcone, Fabiana Conciatori, Chiara Bazzichetto, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 2870-2870
Open Access | Times Cited: 100
The multifaceted anti-cancer effects of BRAF-inhibitors
Laura Croce, Francesca Coperchini, Flavia Magri, et al.
Oncotarget (2019) Vol. 10, Iss. 61, pp. 6623-6640
Open Access | Times Cited: 69
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
Reinhard Dummer, Paolo A. Ascierto, Paul Nathan, et al.
JAMA Oncology (2020) Vol. 6, Iss. 12, pp. 1957-1957
Closed Access | Times Cited: 53
BRAFV600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis
Kaixuan Zeng, Zhe Wang, Koichi Ohshima, et al.
OncoImmunology (2016) Vol. 5, Iss. 7, pp. e1185582-e1185582
Open Access | Times Cited: 48
Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma
Filipe V. Almeida, Stephen M. Douglass, Mitchell E. Fane, et al.
Pigment Cell & Melanoma Research (2018) Vol. 32, Iss. 2, pp. 237-247
Open Access | Times Cited: 39
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
Alessandro Nepote, Gianluca Avallone, Simone Ribero, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 3, pp. 828-828
Open Access | Times Cited: 22
Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
Maximilian Haist, Henner Stege, Michael Kuske, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 2, pp. 481-505
Open Access | Times Cited: 11
Mechanisms of Altered Immune Response in Skin Melanoma.
Radu-Florin Fruntealată, Matei Marius, Ianis Kevyn Stefan Boboc, et al.
PubMed (2024) Vol. 49, Iss. 3, pp. 297-311
Closed Access | Times Cited: 4
Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity
Manali S. Phadke, Zhihua Chen, Jiannong Li, et al.
Cancer Immunology Research (2021) Vol. 9, Iss. 5, pp. 554-567
Open Access | Times Cited: 23
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
Nicolas Jacquelot, Jonathan M. Pitt, David Enot, et al.
OncoImmunology (2017) Vol. 6, Iss. 8, pp. e1299303-e1299303
Open Access | Times Cited: 26
Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
T. Jung, Maximilian Haist, Michael Kuske, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9890-9890
Open Access | Times Cited: 18
Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanoma
Tatjana Zablocka, Madara Kreišmane, Dace Pjanova, et al.
Oncology Letters (2022) Vol. 25, Iss. 1
Open Access | Times Cited: 14
Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment
Davide Quaresmini, Michele Guida
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 20
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients
Enrico Berrino, Antonella Balsamo, Alberto Pisacane, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100133-100133
Open Access | Times Cited: 15
Addressing the importance of melanoma tumor‑infiltrating lymphocytes in disease progression and clinicopathological characteristics
Tatjana Zablocka, Anna Nikolajeva, Madara Kreišmane, et al.
Molecular and Clinical Oncology (2021) Vol. 15, Iss. 6
Open Access | Times Cited: 12
Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR
Elena-Georgiana Dobre, Luciana Nichita, Cristiana Popp, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2308-2308
Open Access | Times Cited: 1
The Expression of Forkhead Box P3 T Regulatory Lymphocytes as a Prognostic Factor in Malignant Melanomas
Vlad Alexandru Gâta, Andrei Pașca, Andrei Roman, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6377-6377
Open Access | Times Cited: 1
Molecular profiling of follicular variant of papillary thyroid cancer reveals low-risk noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A paradigm shift to reduce aggressive treatment of indolent tumors
Amit Agarwal, Nelson George, Niraj Kumari, et al.
Indian Journal of Endocrinology and Metabolism (2018) Vol. 22, Iss. 3, pp. 339-339
Open Access | Times Cited: 12
Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer
Yara O. Aghabi, Alia Yasin, J KENNEDY, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 9
In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas
Jung Hee Kim, Hyeyoon Kim, Kisoon Dan, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 8
EXPRESSION AND CLINICAL CORRELATION OF PD-1/PD-L1 AND VE1(BRAFP.V600E) IN PEDIATRIC LANGERHANS CELL HISTIOCYTOSIS
Sneha Tandon, Sheila Weitzman, Brooklyn Joyce, et al.
Mediterranean Journal of Hematology and Infectious Diseases (2023) Vol. 15, Iss. 1, pp. e2023035-e2023035
Open Access | Times Cited: 2
Research Progress of CICs in Immunotherapy of Liver Cancer
宇君 聂
Advances in Clinical Medicine (2024) Vol. 14, Iss. 07, pp. 219-226
Closed Access
Revisiting the melanomagenic pathways and current therapeutic approaches
Pavan Kumar Dhanyamraju, Solomon O. Rotimi, Priyanjali Bhattacharya, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 10, pp. 9651-9671
Open Access | Times Cited: 2
Regulatory T-cell expansion in oral and maxillofacial Langerhans cell histiocytosis
Chuhan Zhang, Jingyi Gao, HE Jiang-hai, et al.
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (2020) Vol. 130, Iss. 5, pp. 547-556
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top